Scalper1 News
Biotech FibroGen (FGEN) jumped 23% Monday to 33.83, a new high for a stock that went public at 18 on Nov. 13. FibroGen stock rose along with several other players in the liver-disease field, including Intercept Pharmaceuticals (ICPT), Conatus (CNAT) and Raptor Pharmaceuticals (RPTP), after the journal Hepatology published the results of a workshop between the FDA and the American Association for the Study of Liver Disease (AASLD), which laid out Scalper1 News
Scalper1 News